NVCT - Rega Nyata Tumbas Perusahaan Kanthi Wutuh nuvectis.com

Nuvectis Pharma, Inc. (NVCT) operates in a segment with colossal demand for effective cancer treatments, where the need for new therapies remains independent of economic downturns. The business faces intense pressure from global pharmaceutical behemoths and risks of clinical trial delays. This chart illustrating the company's valuation history is 577.19, while unique patents and strict FDA oversight provide asset protection.

Nuvectis Pharma - Nilai Perusahaan NVCT (periode 23.11.2025 - 29.10.2026)

Ringkesan rincian data analitis Nuvectis Pharma, Inc. (NVCT)

- rega saham lan target rega konsensus:

Bagan rega Nuvectis Pharma Inc.|NVCT - Prakiraan konsensus analis

- statistik kapitalisasi pasar:

Biji pasar Nuvectis Pharma|NVCT - Rega Nyata Tumbas Perusahaan Kanthi Wutuh

- data nilai buku modal saham:

Rega Buku Saham Nuvectis Pharma|NVCT - Kapitalisasi Buku|Rasio Nilai Pasar marang Ekuitas nuvectis.com|NVCT - Total Aset Perusahaan

- indikator total utang lan likuiditas perusahaan:

- rincian asil keuangan lan kelipatan valuasi:

NVCT - Bathi resik perusahaan

Ringkesan analitik perusahaan:Nuvectis Pharma, Inc.

Produk asil prodhuksi Nuvectis Pharma Inc.

Enterprise Value is used for an objective asset valuation, combining market capitalization with net debt to determine the total cost of acquiring the business. By analyzing the market value while accounting for liquidity and liabilities at the level of 577.19, an investor sees the real financial weight of Nuvectis Pharma, Inc. (NVCT), which in biopharmaceuticals depends not on economic cycles, but on the volume of R&D capital and regulatory successes.

Pesaing Nuvectis Pharma, Inc. (NVCT)